TE-8105 Could Stretch GLP-1 Injections to Every Two Weeks. The First Human Study Is Not an Efficacy Trial.

A new GLP-1 drug is being designed around a simple promise: fewer injections. TE-8105 is an experimental, long-acting GLP-1 receptor agonist that its developers hope can be injected once every two weeks rather than once a week. The first peer-reviewed human study is now available, and it gives researchers a reason to continue. It does not yet give patients a reason to switch.

That distinction matters because the most eye-catching number comes from only eight people. Four of them maintained at least 5% weight loss by their final study visit. The average loss across that group was much smaller, 2.06%, and two participants did not lose weight at all. There was no placebo group.

The useful result is less glamorous: TE-8105 remained in the body long enough to make a biweekly schedule plausible. Whether that schedule can deliver reliable weight loss with tolerable side effects still needs a proper randomized trial.

What researchers tested

The study enrolled 38 adults with overweight or obesity who did not have type 2 diabetes. Participants were otherwise medically healthy. The trial was conducted at one site, used an open-label design, and gave every participant active TE-8105.

The first 24 participants entered single-dose cohorts. Six people in each cohort received 0.5, 0.75, 1.5, or 3.0 mg by subcutaneous injection. Researchers followed them for 43 days to examine exposure, clearance, and early safety.

Another 14 participants entered the multiple-dose part. Six received a flat 1.0 mg dose every two weeks for five doses. Eight followed a longer titration schedule: two doses each at 1.5, 2.0, and 2.5 mg, followed by three doses at 3.0 mg. Every injection was two weeks apart, and that group's treatment period lasted 18 weeks.

This was a pharmacology study. Its main job was to learn how the drug behaves in people and whether the tested doses created an obvious safety problem. Body weight, waist measurements, fasting glucose, insulin, and HbA1c were exploratory measures. The study was not sized or controlled to prove that TE-8105 causes weight loss.

Why TE-8105 lasts longer

TE-8105 combines a GLP-1 analog with a peptide linker and a bundle containing two fatty-acid chains. The fatty-acid portion is intended to bind the drug tightly to albumin, a common protein in blood. Albumin binding slows the rate at which a peptide is cleared.

That engineering appears to have produced prolonged exposure. Across the single-dose cohorts, TE-8105 had an elimination half-life of roughly 119 to 126 hours. The paper summarizes it as about 120 hours, or five days.

A five-day half-life does not automatically equal a fourteen-day dosing interval. Drug concentration, receptor activity, peak-to-trough variation, tolerability, and the exposure needed for a clinical effect all matter. The study also found that exposure rose more than proportionally when the dose increased from 1.5 to 3.0 mg. The authors suggest that the higher injection concentration may have changed absorption, but they describe this as a hypothesis that requires more investigation.

The multiple-dose results add another complication. The flat 1.0 mg schedule showed little accumulation. The titration schedule did accumulate: the reported mean ratio was 3.75 for peak concentration and 3.00 for total exposure when the first and last doses were compared without adjusting for dose. That is not necessarily a failure, since the dose was intentionally raised over time. It does mean that the final schedule cannot be chosen from half-life alone.

The weight-loss number needs context

The titration cohort produced the result most likely to travel through headlines. Five of eight participants reached at least 5% weight loss at some point after baseline. Four still met that threshold at the end-of-study visit. The mean change for the cohort was a 2.06% decrease.

Those figures can coexist because the response was uneven. Five people lost weight, one was roughly weight neutral, and two gained a small amount. Four of the five responders were still losing weight near the end of treatment, according to the paper. The observation is encouraging enough to test again. It is far too unstable to use as an estimate of what future patients should expect.

The six-person flat-dose cohort makes the picture even less tidy. Mean weight rose from 91.37 kg at baseline to 95.42 kg at the end-of-study or early-termination visit, a mean increase of 4.05 kg. The reported 95% confidence interval was 0.26 to 7.84 kg, with a P value of 0.0403.

That increase does not prove that the drug caused weight gain. A six-person, uncontrolled cohort is highly vulnerable to individual variation, and the 1.0 mg dose may have been too low. Still, the result belongs in any honest account of the trial. It prevents the study from being reduced to "half of participants lost 5%."

Researchers also reported trends toward higher insulin and lower fasting glucose and HbA1c in both multiple-dose cohorts, but the paper did not present those data in detail. Three people in the titration group began in the prediabetes HbA1c range. All three had lower HbA1c, and two moved below that range by the end. With no control group and only three cases, this is a signal for future study, not evidence of diabetes prevention.

What the safety data show

No participant had a severe treatment-emergent adverse event, a serious adverse event, or an adverse event that caused withdrawal. That is reassuring for a first exposure in humans, but the study is too small to detect uncommon harms.

Treatment-related adverse events were common. They occurred in 19 of 24 people in the single-dose part and 13 of 14 in the multiple-dose part. Most events were mild and resolved.

The pattern looked familiar for a GLP-1 receptor agonist. Treatment-related nausea affected 16.7% of participants in Part A and 21.4% in Part B. Vomiting occurred in 4.2% and 7.1%, while constipation occurred in 4.2% and 7.1%. One person in the titration cohort had moderate nausea and vomiting that required an antiemetic. The highest single dose also produced more gastrointestinal trouble than lower doses.

Two participants in the single-dose part had mildly elevated amylase and/or lipase from baseline. The investigators reported no other clinically significant abnormalities in vital signs, laboratory tests, or electrocardiograms.

These findings support larger trials. They cannot establish a complete safety profile. Thirty-eight participants provide little power to identify rare pancreatic, gallbladder, cardiovascular, allergic, or other events that may appear only after broader and longer exposure.

What the study cannot answer

The absence of a placebo group is the central limitation. Everyone knew they were receiving a GLP-1 drug, and the common effects of that class can make blinding difficult anyway. Open-label design may be reasonable for dose escalation, but it weakens every claim about body weight and metabolic outcomes.

The multiple-dose evidence comes from 14 people, split across two different regimens. The study took place at one site, and most participants were White. The median age was 41.5 years in the single-dose part and 29.5 years in the multiple-dose part. Participants were selected for being otherwise healthy, so the findings may not transfer cleanly to people with type 2 diabetes, cardiovascular disease, fatty liver disease, or more severe obesity.

The sponsor relationship also deserves disclosure. Immunwork funded the study. Several authors were employees of Immunwork or T-E Meds, and other investigators had consulting or contract relationships. That does not invalidate the data. It raises the value of independent replication and of later trials with preregistered efficacy endpoints.

The Oria take

TE-8105 has cleared an important but early hurdle. Human exposure lasted long enough to justify testing a two-week schedule, and the trial did not uncover a severe safety problem in 38 participants. The varied weight responses show why the next trial needs more people, a placebo or active comparator, and a fixed primary endpoint.

Convenience is a legitimate drug feature. Fewer injections could reduce treatment burden, especially during long-term weight maintenance. Yet dosing frequency matters only if exposure remains effective and tolerable through the full interval. TE-8105's 120-hour half-life and dose-related accumulation make that an open question rather than a solved engineering problem.

For now, TE-8105 is an investigational compound with first-in-human pharmacokinetic data. It is not approved, there is no validated consumer protocol, and the study does not support self-experimentation or comparison shopping against semaglutide or tirzepatide.

Sources

1. Chuang YS, Wright JD, Wong MT, et al. "First-in-Human Study of a Long-Acting GLP-1 Receptor Agonist (TE-8105) in Overweight or Obese Adults Without Type 2 Diabetes Mellitus." Journal of Clinical Pharmacology. 2026;66(8):e70224. https://pmc.ncbi.nlm.nih.gov/articles/PMC13421993/
2. PubMed record, PMID 42530137. https://pubmed.ncbi.nlm.nih.gov/42530137/
3. DOI record. https://doi.org/10.1002/jcph.70224
4. Crossref publication metadata. https://api.crossref.org/works/10.1002/jcph.70224

Evidence grade: C. TE-8105 has peer-reviewed human pharmacokinetic and short-term safety data, but weight loss was exploratory in a small, uncontrolled, open-label study. No randomized efficacy estimate is available.

Medical disclaimer: This article is for education and does not provide medical advice, diagnosis, or treatment. TE-8105 is investigational and is not an approved medication or a basis for self-directed dosing. Discuss weight management and GLP-1 treatment with a licensed clinician who can review your health history, current medicines, and local regulatory options. Oria exists to make peptide evidence easier to evaluate, not to replace individualized care.